Hydroxy, Bonded Directly To Carbon, Attached Directly Or Indirectly To The Acyclic Carbon Or Chain By Acyclic Nonionic Bonding (e.g., Beta Hydroxy Phenethylamines, Etc.) Patents (Class 514/653)
-
Publication number: 20140080916Abstract: Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.Type: ApplicationFiled: February 1, 2012Publication date: March 20, 2014Applicant: Cognition Therapeutics, Inc.Inventors: Gilbert M. Rishton, Susan Catalano
-
Publication number: 20140080836Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: November 19, 2013Publication date: March 20, 2014Applicant: GALDERMA LABORATORIES INC.Inventors: Michael GRAEBER, Christian LOESCHE, Philip FREIDENREICH, Jack A. DEJOVIN, Isabelle Jean DEJOVIN, Yin-sang LIU, Matthew James LEONI
-
Publication number: 20140079782Abstract: The present invention relates to active substances in particulate form, to methods for preparing them and to their uses. The present invention provides particulate powders, such as might be of use for delivery using a dry powder inhaler (DPI) or similar delivery device, having properties which may be beneficial to the DPI delivery process.Type: ApplicationFiled: September 18, 2012Publication date: March 20, 2014Applicant: NEKTAR THERAPEUTICSInventors: PETER YORK, Boris Yu Shekunov, Mahboob Ur Rehman, Jane Catherine Feeley
-
Publication number: 20140072610Abstract: A bioabsorbable tracheal stent is provided. The bioabsorbable stent comprises a biodegradable polymer, wherein the “ biodegradable polymer comprises about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. A drug is dispersed within or dissolved in the biodegradable polymer. In a second and third aspect, the invention relates to methods of manufacturing a bioabsorbable tracheal stent. The first method includes forming a solution comprising a biodegradable polymer and a drug, the biodegradable polymer comprising about 0 to 30 wt % glycerol, polyethylene glycol, triethyl citrate, or mixture thereof. The method further comprises casting the solution to form the bioabsorbable tracheal stent.Type: ApplicationFiled: March 21, 2012Publication date: March 13, 2014Applicants: NATIONAL UNIVERSITY OF SINGAPORE, NANYANG TECHNOLOGICAL UNIVERSITYInventors: Subramanian Venkatraman, Herr Cheun Anthony Ng, Yin Chiang Freddy Boey, Hsueh Yee Lynne Lim
-
Publication number: 20140073562Abstract: A nasal delivery device for and method of delivering a substance, preferably comprising oxytocin, non-peptide agonists thereof and antagonists thereof, preferably as one of a liquid, as a suspension or solution, or a powder to the nasal airway of a subject, preferably the posterior region of the nasal airway, and preferably the upper posterior region of the nasal airway which includes the olfactory bulb and the trigeminal nerve, and preferably in the treatment of neurological conditions and disorders.Type: ApplicationFiled: March 15, 2012Publication date: March 13, 2014Applicant: OPTINOSE ASInventor: Per Gisle Djupesland
-
Publication number: 20140065219Abstract: Methods for making inhalable composite particles comprising a pharmaceutically-active agent, the method comprising: a) providing composite particles comprising a millable grinding matrix and a solid pharmaceutically-active agent, wherein the pharmaceutically-active agent has an median particle size on a volume average basis between 50 nm and 3 ?m; and b) milling the composite particles in a mill without milling bodies for a time period sufficient to produce inhalable composite particles having a mass median aerodynamic diameter between 1 ?m and 20 ?m are described.Type: ApplicationFiled: February 28, 2013Publication date: March 6, 2014Inventors: William H. Bosch, Matthew Callahan, Felix Meiser, Marck Norret, Adrian Russell
-
Publication number: 20140057837Abstract: Methods for increasing the amount of brown adipose tissue in a subject, of increasing the ratio of brown fat to white fat in a subject, or for effecting a change in white adipose tissue to become brown adipose tissue in a subject include the administration of one or more agents. The agent can increase or induce hypothalamic expression of BDNF, can be a TrkB receptor agonist or a beta-3 adrenergic receptor agonist, or encode an agonist that modulates a hypothalamic-adipocyte axis.Type: ApplicationFiled: August 21, 2013Publication date: February 27, 2014Inventors: Matthew During, Lei Cao
-
Publication number: 20140051766Abstract: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.Type: ApplicationFiled: August 12, 2013Publication date: February 20, 2014Applicant: Novartis AGInventors: Guido Jordine, Michael Mutz
-
Publication number: 20140038949Abstract: The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.Type: ApplicationFiled: February 17, 2012Publication date: February 6, 2014Applicants: IRM LLC, The Scripps Research InstituteInventors: Peter Schultz, Luke Lairson, Vishal Deshmukh, Costas Lyssiotis
-
Publication number: 20140039063Abstract: The invention provides methods for predicting the risk for a subject of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent as well as methods for reducing a subject's risk of exacerbation of an inflammatory disease of the airways upon exposure to an environmental agent.Type: ApplicationFiled: January 4, 2012Publication date: February 6, 2014Applicant: NATIONAL JEWISH HEALTHInventor: Nathan Rabinovitch
-
Publication number: 20140039048Abstract: Methods are provided herein for the treatment of ophthalmic diseases or conditions such as an ophthalmic disease or disorder associated with diabetes in a patient. Also provided herein are methods of treating retinopathy of prematurity in a patient. Further, provided herein are methods for treating wet age-related macular degeneration in a patient. The methods comprise administration of compounds disclosed herein to a patient in need thereof that inhibit or slow one or more signs or symptoms of such conditions.Type: ApplicationFiled: May 3, 2013Publication date: February 6, 2014Applicant: Acucela Inc.Inventor: Acucela Inc.
-
Patent number: 8642078Abstract: A sustained release pharmaceutical composition comprising coating comprising at least one water-insoluble permeable polymer and at least one water soluble polymer and homogenous cores containing only tolterodine or a salt thereof and microcrystalline cellulose is described.Type: GrantFiled: March 29, 2007Date of Patent: February 4, 2014Assignee: Lek Pharmaceuticals, D.D.Inventors: Igor Legen, Polonca Kuhar
-
Publication number: 20140031321Abstract: The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.Type: ApplicationFiled: January 14, 2013Publication date: January 30, 2014Applicant: CELTAXSYS, INC.Inventor: Erica Brook Goodhew
-
Publication number: 20140024677Abstract: Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procaterol to an individual are provided.Type: ApplicationFiled: April 9, 2013Publication date: January 23, 2014Applicant: MUSC Foundation For Research DevelopmentInventors: Rick G. SCHNELLMANN, Craig C. BEESON, Yuri K. PETERSON
-
Publication number: 20140017346Abstract: Disclosed is a gelatin-free soft caramel including a soft caramel base mass that contains at least one polysaccharide hydrocolloid as texturing agent, a crystalline sweetener phase formed by isomaltulose, and a noncrystalline sweetener phase, wherein the caramel is gelatin-free. It can be made by providing a noncrystalline sweetener phase by dissolving at least one soluble sweetener in water, adding polysaccharide hydrocolloid, fat component, emulsifier and a part of the total amount of the isomaltulose to the noncrystalline sweetener phase, steam heating the mixture to a temperature of at least 100° C., adding the remaining isomaltulose to the heated mixture while stirring, incorporating air into the mixture and cooling.Type: ApplicationFiled: September 16, 2013Publication date: January 16, 2014Applicant: Sudzucker Aktiengesellschaft Mannheim/OchsenfurtInventors: Jorg Bernard, Kowalczyk Jorg
-
Patent number: 8628805Abstract: A stabilized composition comprising at least one adrenergic compound and at least one antioxidant selected from the group consisting of a bisulfate, a metabisulfite and a sulfite compound.Type: GrantFiled: June 4, 2010Date of Patent: January 14, 2014Assignee: ALK AGInventors: Alan J. Baillie, Kenneth MacDonald, Pamela Porteous, Simon Hendry
-
Publication number: 20140011809Abstract: A method and means for delivery of drugs to the chorio-retina and the optic nerve head which comprises contacting the surface of the eye with an effective amount of drug for treatment of chorio-retina and optic nerve head and a physiologically acceptable adrenergic agent for enhancing delivery of the drug to these tissues in an ophtalmologically acceptable carrier, said adrenergic agent being selected from the group consisting of alpha adrenergic agonist agents, derivatives of the alpha adrenergic agonist agents, beta-blocking agents, derivatives of the beta-blocking agents and mixtures thereof.Type: ApplicationFiled: June 7, 2013Publication date: January 9, 2014Inventor: Raouf Rekik
-
Publication number: 20140011884Abstract: Use of an S1P receptor modulator in the treatment or prevention of a disease or condirion dependent on brain-derived neurotrophic factor (BDNF) expression.Type: ApplicationFiled: May 13, 2013Publication date: January 9, 2014Inventors: Yves-Alain BARDE, Graeme BILBE, Ruben DEOGRACIAS, Rainer R, KUHN, Tomoya MATSUMOTO, Anis Khusro MIR, Anna Svenja SCHUBART
-
Publication number: 20140011885Abstract: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.Type: ApplicationFiled: September 16, 2013Publication date: January 9, 2014Applicant: Novartis AGInventors: Tomoyuki Oomura, Madhusudhan Pudipeddi, Colleen Ruegger, Alan Edward Royce, Masaki Sasaki, Tokuhiro Tamura
-
Patent number: 8623851Abstract: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof, and a steroidal anti-inflammatory agent. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.Type: GrantFiled: November 24, 2009Date of Patent: January 7, 2014Assignee: Mylan Specialty L.P.Inventors: Partha S. Banerjee, Imtiaz A. Chaudry, Stephen Pham
-
Publication number: 20140005135Abstract: Disclosed is a stable liquid formulation for parenteral injection comprising a biocompatible non-aqueous solvent and a small molecule drug, or a salt thereof, solubilized within the non-aqueous solvent, wherein the liquid formulation comprises less than 10% by weight residual water, and wherein the volume of the liquid formulation to be parenterally injected is from 0.1 ?l to 3 ml.Type: ApplicationFiled: March 14, 2013Publication date: January 2, 2014Applicant: XERIS PHARMACEUTICALS, INC.Inventors: Steven J. Prestrelski, Nancy Scott
-
Patent number: 8613948Abstract: 1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastro-intestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.Type: GrantFiled: November 15, 2012Date of Patent: December 24, 2013Assignee: Norgine BVInventors: Norman Barras, Jeffrey Martin Thompson
-
Patent number: 8603497Abstract: An object of the present invention is to provide a composition for local anesthesia to be added to a local anesthetic drug, the composition showing a sustained local anesthetic effect and having high safety. The object is achieved by a composition for local anesthesia including a drug antagonistic to a systemic action of adrenaline, i.e., an ?2 receptor agonist. The ?2 receptor agonist can be added to a local anesthetic agent together with adrenaline or a salt thereof to reduce the amount of adrenaline to be added as compared to that of adrenaline or a salt thereof alone. As a result, a sustained local anesthetic effect is obtained and local anesthesia can be performed with high safety.Type: GrantFiled: October 29, 2009Date of Patent: December 10, 2013Assignee: National University Corporation Okayama UniversityInventors: Takuya Miyawaki, Tatsushi Yoshitomi
-
Patent number: 8597616Abstract: The present disclosure relates to systems, methods, and formulations for the pulmonary administration of one or more therapeutic agents, in dry powder form, in a single, large dose quantity. These formulations, methods, and systems are useful in the treatment of patients suffering from toxic or harmful gas exposure, such as nerve gas exposure, as well as in the treatment of patients suffering from diseases of the pulmonary system, including tuberculosis, cystic fibrosis, and chronic obstructive pulmonary disease (COPD).Type: GrantFiled: October 22, 2008Date of Patent: December 3, 2013Assignee: Board of Regents of the University of Texas SystemInventors: Edward R. Kraft, Stephen L. Hoskins, Perenlei Enkhbaatar, Daniel L. Traber
-
Publication number: 20130309199Abstract: The present invention relates to the use of an R-enantiomer of a compound according to the following formula (I) (I), wherein R1 or R2 is a group selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH2CH2CH2CH3 or can be taken together with another to give a cyclopropyl ring, a cyclobutyl ring, a cyclopentyl ring, or a cyclohexyl ring, R3 is a group selected from —COOH, —COOR6, —CONH2, —CONHR6, —CONR6R7, —CONHSO2R6, —COO—(CH2)3—CH2OH, —COO—(CH2)4—ONO2, —COO—PhOCH3—C2H2—COO—(CH2)4—ONO2, tetrazolyl, and a —COOH bioisostere, R4 or R5 is a group selected from —Cl, —F, —Br, —I, —CF3, —OCF3, —SCF3, —OCH3, —OCH2CH3, —CN, —CH?CH2, —CH2OH, and —NO2, R6 of R7 is a group selected from —CH3, —CH2CH3, —CH2CH2CH3, and —CH2CH2CH2CH3, and m or n is an integer selected from 0, 1, 2, and 3, or a nitro-variant of said compound, and pharmaceutically acceptable salts of said compound, preferably Tarenflurbil (R-Flurbiprofen), for use in the treatment of multiple sclerosis (MS).Type: ApplicationFiled: November 3, 2011Publication date: November 21, 2013Inventors: Irmgard Tegeder, Gerd Geisslinger
-
Publication number: 20130303490Abstract: The invention relates to compounds which are agonists of at least one receptor selected from S1PR1, S1PR2, S1PR3, S1PR4 and S1PR5 receptors, for use in methods for treating HIV infections in humans or animals.Type: ApplicationFiled: December 12, 2011Publication date: November 14, 2013Applicant: Centre National De La Recherche Scientifique-CNRSInventors: Vincent Francois, Pierre Corbeau, Charline Duquenne
-
Publication number: 20130295174Abstract: In one aspect, the present invention features a tablet including a first region and a second region, wherein: (i) the first region and the second region each include at least 10%, by volume, of the tablet; (ii) the first region includes a pharmaceutically active agent and the composition of the first region is different from the composition of the second region; (iii) the first region has a density less than about 0.8 g/cc; and (iv) the first region disintegrates in the mouth when placed on the tongue in less than about 30 seconds; wherein the shape of the tablet includes two opposing major faces separated by a side wall, and the interface between the first region and the second region is along at least one major face of the tablet.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Applicant: McNeil-PPC, Inc.Inventors: Harry S. Sowden, Gerard P. McNally, Oliver Anderson, William J. Stuhl, Jen-Chi Chen, Kenneth Day, Christopher E. Szymczak
-
Publication number: 20130296416Abstract: Provided are methods of treating heart failure in children using B1-selective adrenergic receptor antagonists, alone or in combination with other agents, including B-2-selective adrenergic receptor agonists.Type: ApplicationFiled: August 25, 2011Publication date: November 7, 2013Applicant: The Regents of the University of Colorado, A Body CorporateInventors: Brian Stauffer, Carmen Sucharov, Shelley Miyamoto
-
Publication number: 20130289127Abstract: Disclosed are compounds of formula I wherein R1, R2, R5 and R6 are as defined in the claims; such compounds have interesting pharmacological properties.Type: ApplicationFiled: June 13, 2013Publication date: October 31, 2013Inventors: Ernst Küsters, Lukas Oberer, Gottfried Sedelmeier
-
Publication number: 20130281540Abstract: The invention presently disclosed is a method for the administration of parenteral medication to a person via subcutaneous delivery designed and intended to facilitate the quick, safe and effective administration of such medication, the method having implications in the treatment of a host of conditions and ailments. As conceived, the inventor contemplates the method having particularized utility in the administration of epinephrine to a person suffering from the life-threatening condition of anaphylaxis.Type: ApplicationFiled: March 27, 2013Publication date: October 24, 2013Inventor: Borislav M. MRAVKOV
-
Publication number: 20130281541Abstract: Disclosed is a new use for sphingosine-1-phosphate (S1P) receptor agonists in the treatment of progressive dementia or brain degenerative diseases.Type: ApplicationFiled: June 18, 2013Publication date: October 24, 2013Inventors: Volker Brinkmann, Nicole Kaneider, Christian J. Wiedermann
-
Publication number: 20130274280Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable gelled oil-in-water emulsion containing a drug of abuse.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes, Magnus N. Hattrem
-
Publication number: 20130273152Abstract: This invention provides an oral pharmaceutical composition comprising a physiologically tolerable shell containing a drug of abuse within an oil comprising physiologically tolerable unsaturated fatty acids.Type: ApplicationFiled: April 11, 2011Publication date: October 17, 2013Applicant: AYANDA GROUP ASInventors: Kurt Ingar Draget, Ingvild Johanne Haug, Steinar Johan Engelsen, Tore Seternes
-
Publication number: 20130253065Abstract: The present invention is directed toward particles for delivery of epinephrine to the respiratory system and methods for treating a patient in need of epinephrine. The particles and respirable compositions comprising the particles of the present invention described herein comprise the bioactive agent epinephrine, or a salt thereof, as a therapeutic agent. The particles are preferably formed by spray drying. Preferably, the particles and the respirable compositions are substantially dry and are substantially free of propellents. In a preferred embodiment, the particles have aerodynamic characteristics that permit targeted delivery of epinephrine to the site(s) of action.Type: ApplicationFiled: March 6, 2013Publication date: September 26, 2013Applicant: Civitas Therapeutics, Inc.Inventors: Richard P. Batycky, Giovanni Caponetti, Mariko Childs, Elliot Ehrich, Karen Fu, Jeffrey S. Hrkach, Wen-I Li, Michael M. Lipp, Mei-Ling Pan, Jason Summa
-
Publication number: 20130253064Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are styrenyl derivative compounds, including but not limited to stilbene derivative compounds, and compositions comprising these compounds, that are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: March 7, 2013Publication date: September 26, 2013Inventors: Ian Leslie Scott, Vladimir Aleksandrovich Kuksa, Anna Gall, Mark W. Orme, Jennifer Gage, Thomas L. Little, JR., Qin Jiang, Lana Michele Rossiter, Kevin F. McGee, JR., Ryo Kubota
-
Publication number: 20130253066Abstract: The present invention relates to new uses of S1P receptor modulator or agonist such as fingolimod, for reducing or delaying the progression of cerebral atrophy.Type: ApplicationFiled: May 20, 2013Publication date: September 26, 2013Inventors: Shreeram Aradhye, Ana DE VERA
-
Publication number: 20130243828Abstract: The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent.Type: ApplicationFiled: September 29, 2011Publication date: September 19, 2013Applicant: PULMATRIX, INC.Inventors: Michael M. Lipp, Jean C. Sung
-
Publication number: 20130243837Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: April 15, 2013Publication date: September 19, 2013Applicant: Galderma Laboratories Inc.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Publication number: 20130237607Abstract: The present invention provides effective and safe medicaments for the treatment of connective tissue diseases of the skin, particularly with respect to the treatment of cutaneous forms of Lupus Erythematous. The medicaments comprise as the therapeutically active ingredient a beta2 adrenoceptor agonist. The invention furthermore relates to dermatological compositions without skin sensitization properties and which contain enantiomerically pure or enriched R-enantiomers of a beta2 adrenoceptor agonist.Type: ApplicationFiled: April 22, 2013Publication date: September 12, 2013Applicant: Astion Development A/SInventors: Morten Sloth WEIDNER, Hans Christian Wulf
-
Patent number: 8529928Abstract: Biodegradable polymers incorporating biomolecules and methods of their use are provided. Certain aspects provide biomolecules crosslinked with diglycidyl esters. The disclosed compositions have numerous applications including cellular regeneration, wound healing, and cellular differentiation.Type: GrantFiled: July 6, 2007Date of Patent: September 10, 2013Assignee: Georgia Tech Research CorporationInventors: Yadong Wang, Blaine Zern, Christiane Gumera
-
Patent number: 8530522Abstract: The present invention relates to crystalline forms and hydrates of 2-Amino-2-[2-(4-C2-20-alkyl-phenyl)ethyl]propane-1,3-diol, and to the use thereof, in particular in the treatment or prevention of various autoimmune conditions.Type: GrantFiled: November 10, 2009Date of Patent: September 10, 2013Assignee: Novartis AGInventors: Guido Jordine, Michael Mutz
-
Patent number: 8519006Abstract: Disclosed is the use of sphingosine-1-phosphate (S1P) receptor agonists, preferably 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol, in the treatment of progressive dementia or brain degenerative diseases.Type: GrantFiled: September 17, 2010Date of Patent: August 27, 2013Assignee: Novartis AGInventors: Volker Brinkmann, Nicole Kaneider, Christian J Wiedermann
-
Publication number: 20130213398Abstract: The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a subject having a respiratory disease and/or infection.Type: ApplicationFiled: August 26, 2011Publication date: August 22, 2013Inventors: Michael M. Lipp, Jean C. Sung, Robert W. Clarke, David L. Hava
-
Publication number: 20130209562Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.Type: ApplicationFiled: March 13, 2013Publication date: August 15, 2013Applicant: ALZA CORPORATIONInventor: ALZA CORPORATION
-
Publication number: 20130209566Abstract: The present invention provides a novel nanoparticle drug delivery system generated from poly(ortho ester) polymers with sustained drug release capability and can be functionalized to allow for systemic delivery to various organ systems throughout the body. One important aspect of this invention is that the nanoparticle drug delivery system generated from poly(ortho ester) polymers encapsulate several types of drugs in poly(ortho ester) nanoparticles, including but not limited to lipophilic, hydrophilic small and large molecules and also hydrophilic and lipophilic dyes by adopting appropriate emulsion techniques. These poly(ortho ester) nanoparticles are biodegradable, biocompatible and controlled release drug delivery system with zero order kinetics, which can be used in various biomedical applications such as eye-related diseases, cancer, arthritis, etc.Type: ApplicationFiled: February 14, 2013Publication date: August 15, 2013Inventors: MONICA JABLONSKI, MALLIKA PALAMOOR
-
Publication number: 20130210835Abstract: A composition of an antitussive, a decongestant, or an antihistamine to treat respiratory and oral pharyngeal congestion and related symptoms in a patient.Type: ApplicationFiled: June 13, 2011Publication date: August 15, 2013Applicant: GM PHARMACEUTICAL, INCInventor: Odes W. Mitchell
-
Publication number: 20130203859Abstract: A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound.Type: ApplicationFiled: March 15, 2013Publication date: August 8, 2013Applicant: GALDERMA LABORATORIES, INC.Inventor: GALDERMA LABORATORIES, INC.
-
Publication number: 20130203830Abstract: The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation.Type: ApplicationFiled: April 18, 2011Publication date: August 8, 2013Applicant: SULFATEQ B.V.Inventors: Fatemeh Talaei, Robert Henk Henning, Adrianus C. Van der Graaf
-
Publication number: 20130197096Abstract: The present invention relates generally to compositions and methods for treating neurodegenerative diseases and disorders, particularly ophthalmic diseases and disorders. Provided herein are alkoxyl derivative compounds and pharmaceutical compositions comprising these compounds. The subject compositions are useful for treating and preventing ophthalmic diseases and disorders, including age-related macular degeneration (AMD) and Stargardt's Disease.Type: ApplicationFiled: September 14, 2012Publication date: August 1, 2013Applicant: Acucela, Inc.Inventors: Ian L. Scott, Vladimir A. Kuksa, Mark W. Orme, Thomas Little, Anna Gall, Feng Hong
-
Publication number: 20130195935Abstract: A solid administration form, protected from parenteral abuse and containing at least one viscosity-increasing agent in addition to one or more active substances that have parenteral abuse potential. The agent forms, when a necessary minimum amount of an aqueous liquid is added, on the basis of an extract obtained from the administration form, a preferably injectable gel that remains visually distinct when introduced into another quantity of an aqueous liquid.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: GRUNENTHAL GMBHInventor: GRUNENTHAL GMBH